Rare diseases
Investigational molecules
Locations
Zahlerweg 10, 6300
Clinical research in atopic dermatitis centers on moderate-to-severe disease across pediatric, adolescent, and adult populations. The sponsor’s studies examine treatment needs in patients whose symptoms remain insufficiently controlled with topical therapy, with attention to ongoing disease management and long-term use.
The therapeutic focus includes chronic inflammatory skin disease, with interest in symptom control, tolerability, and sustained treatment safety.
Galderma S.A. runs clinical trials in conditions such as Dermatitis atopic, Systemic scleroderma, Neurodermatitis, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Phase 2 Study of Nemolizumab for Skin Thickening in Adults with Systemic Sclerosis
BulgariaPharmacokinetics, Safety and Efficacy of Nemolizumab in Infants 6–23 Months with Moderate-to-Severe Atopic Dermatitis
PolandStudy on the Long-Term Safety and Efficacy of Nemolizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis
AustriaStudy on the Long-Term Safety and Effectiveness of Nemolizumab for Patients with Prurigo Nodularis
AustriaStudy on Nemolizumab for Children Aged 2-11 with Moderate-to-Severe Atopic Dermatitis Not Controlled by Topical Treatments
HungaryIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
